ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.

MLA

Noé, Johannes, et al. “ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.” Journal of Thoracic Oncology, vol. 15, no. 4, Apr. 2020, pp. 601–08. EBSCOhost, https://doi.org/10.1016/j.jtho.2019.10.015.

APA

Noé, J., Lovejoy, A., Ou, S.-H. I., Yaung, S. J., Bordogna, W., Klass, D. M., Cummings, C. A., & Shaw, A. T. (2020). ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials. Journal of Thoracic Oncology, 15(4), 601–608. https://doi.org/10.1016/j.jtho.2019.10.015

Chicago

Noé, Johannes, Alex Lovejoy, Sai-Hong Ignatius Ou, Stephanie J. Yaung, Walter Bordogna, Daniel M. Klass, Craig A. Cummings, and Alice T. Shaw. 2020. “ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.” Journal of Thoracic Oncology 15 (4): 601–8. doi:10.1016/j.jtho.2019.10.015.